ABL Diagnostics Publishes its 2025 Annual Financial Report

ABL Diagnostics, based in Woippy, has announced the availability of its 2025 annual financial report. The public and the French Financial Markets Authority (AMF) have access to this document via the company's website. This announcement follows the Board of Directors meeting of April 30, 2025, which approved the annual accounts. Furthermore, an ordinary and extraordinary general meeting of shareholders is scheduled for June 30, 2026, in Paris.

Specializing in molecular biology testing, ABL Diagnostics offers a range of products including solutions for HIV, hepatitis B and C, and other diseases. The company's products are distributed worldwide. Listed on Euronext Paris, ABL continues to expand its microbiology portfolio, generating recurring revenue through its innovative solutions.